LBP PA01
Alternative Names: LBP-PA01Latest Information Update: 23 Feb 2024
At a glance
- Originator Locus Biosciences
- Class Antibacterials; Bacteriophages; Gene therapies
- Mechanism of Action Bacterial DNA degraders; Cell death stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Pseudomonal infections
Most Recent Events
- 23 Feb 2024 Preclinical trials in Pseudomonal infections in USA (unspecified) prior to February 2024 (Locus Biosciences pipeline, February 2024)
- 01 Oct 2023 Janssen Pharmaceuticals is now called Johnson & Johnson Innovative Medicine (Janssen Pharmaceuticals website, October 2023)
- 09 Jan 2019 Locus Biosciences and Janssen Pharmaceuticals enter into a collaboration and license agreement to develop bacteriophage therapeutics